- Home
- MGNI vs VERA Comparison
MGNI vs VERA Comparison
Compare MGNI & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNI
- VERA
- Stock Information
- Founded
- MGNI 2007
- VERA 2016
- Country
- MGNI United States
- VERA United States
- Employees
- MGNI N/A
- VERA N/A
- Industry
- MGNI Computer Software: Programming Data Processing
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- MGNI Technology
- VERA Health Care
- Exchange
- MGNI Nasdaq
- VERA Nasdaq
- Market Cap
- MGNI 2.4B
- VERA 2.0B
- IPO Year
- MGNI N/A
- VERA 2021
- Fundamental
- Price
- MGNI $18.72
- VERA $20.86
- Analyst Decision
- MGNI Strong Buy
- VERA Buy
- Analyst Count
- MGNI 13
- VERA 8
- Target Price
- MGNI $19.23
- VERA $64.63
- AVG Volume (30 Days)
- MGNI 1.9M
- VERA 2.9M
- Earning Date
- MGNI 08-06-2025
- VERA 08-07-2025
- Dividend Yield
- MGNI N/A
- VERA N/A
- EPS Growth
- MGNI N/A
- VERA N/A
- EPS
- MGNI 0.21
- VERA N/A
- Revenue
- MGNI $674,622,000.00
- VERA N/A
- Revenue This Year
- MGNI $0.32
- VERA N/A
- Revenue Next Year
- MGNI $11.02
- VERA N/A
- P/E Ratio
- MGNI $87.36
- VERA N/A
- Revenue Growth
- MGNI 5.59
- VERA N/A
- 52 Week Low
- MGNI $8.22
- VERA $18.53
- 52 Week High
- MGNI $21.29
- VERA $51.61
- Technical
- Relative Strength Index (RSI)
- MGNI 69.84
- VERA 43.65
- Support Level
- MGNI $16.99
- VERA $20.37
- Resistance Level
- MGNI $18.63
- VERA $23.14
- Average True Range (ATR)
- MGNI 0.62
- VERA 1.70
- MACD
- MGNI 0.03
- VERA -0.46
- Stochastic Oscillator
- MGNI 80.91
- VERA 3.88
About MGNI Magnite Inc.
Magnite Inc is one of the supply-side platform providers, or SSP, in online advertising. The firm generate its revenue from the programmatic sale of CTV ad inventory, from mobile online sites and apps, and the remaining from websites accessed via computer.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.